RE:RE:Nothing new Latest MD&A....
In the vaccine segment, the Company has initiated a research project with a large pharmaceutical company to integrate their vaccines into RDT’s strips. Additionally, the Company is collaborating with a US-based vaccine provider to load their Plasma DNA vaccines onto RDT’s strips. Furthermore, the Company is partnering with a US-based university to research the ability to infuse a Fentanyl vaccine into the QuickStrip. This particular vaccine is a unique offering which addresses the growing opioid addiction crisis in North America by curtailing the drug craving. The advantages of sublingual strip technology in the vaccine market are potentially extensive and include:
• Eliminating the need for needles.
• Eliminating the need for cold chain or reconstitution.
• Eliminating the need for qualified health care professional administration.
• Precise and reproducible dosing.
• Cost savings at government and local levels.